S0309, Repository: Blood/Bone Marrow From Pts. With Myeloma, WM, Amyloidosis, or MGUS.

Completed

• Conditions: Smoldering Myeloma; Multiple Myeloma; Amyloidosis; Waldenstrom's Macroglobulinemia; Monoclonal Gammopathy of Undetermined Significance

• Registration Number: NCT00919139
• Lead Sponsor: SWOG Cancer Research Network

Brief Summary

RATIONALE: Collecting and storing samples of blood and bone marrow from patients with cancer to study in the laboratory may help doctors find better ways to ways to treat the cancer.

PURPOSE: The purpose of this study is to collect and store blood and bone marrow samples from patients with multiple myeloma, smoldering myeloma, Waldenstrom's macroglobulinemia, amyloidosis, and monoclonal gammopathy of undetermined significance to be tested in the laboratory.

Detailed Description

OBJECTIVES:

* Maintain and expand tissue repositories of myeloma specimens from uniformly treated Southwest Oncology Group (SWOG) patients with multiple myeloma, smoldering myeloma, Waldenstrom's macroglobulinemia, amyloidosis, or monoclonal gammopathy of undetermined significance.

* Utilize scientific information generated from intergroup and collaborative studies to assist the SWOG Myeloma Committee in the development of new and more effective treatment regimens for these patients.

OUTLINE: Patients receive treatment as directed by the treatment protocols on which they are registered. Specimens of blood and/or marrow are submitted to the Myeloma Repository. The status of the patient (e.g., pre-study, post-remission, or relapse) will be recorded prior to specimen collection.

PROJECTED ACCRUAL: Not specified

Study Timeline

• Study Start: 2003-11
• Study First Submitted: 2009-06-11
• Study First Submitted QC: 2009-06-11
• Study First Posted: 2009-06-12
• Primary Completion: 2010-11
• Study Completion: 2010-11
• Status Verified: 2015-04
• Last Update Submitted: 2015-04-01
• Last Update Posted: 2015-04-03

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 190

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Maintenance and expansion of tissue repositories of myeloma specimens from uniformly treated SWOG patients with multiple myeloma, smoldering myeloma, Waldenstrom's macroglobulinemia, amyloidosis, or monoclonal gammopathy of undetermined significance	7 years
Development of new and more effective treatment regimens for these patients using scientific information generated from intergroup and collaborative studies	7 years

Trial Locations

Locations (207)

Arkansas Cancer Research Center at University of Arkansas for Medical Sciences; 🇺🇸 Little Rock, Arkansas, United States

Alta Bates Summit Comprehensive Cancer Center; 🇺🇸 Berkeley, California, United States

Peninsula Medical Center; 🇺🇸 Burlingame, California, United States

University of California Davis Cancer Center; 🇺🇸 Sacramento, California, United States

California Pacific Medical Center - California Campus; 🇺🇸 San Francisco, California, United States

Sutter Health - Western Division Cancer Research Group; 🇺🇸 San Rafael, California, United States

Sutter Solano Medical Center; 🇺🇸 Vallejo, California, United States

Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center; 🇺🇸 Hartford, Connecticut, United States

M.D. Anderson Cancer Center at Orlando; 🇺🇸 Orlando, Florida, United States

H. Lee Moffitt Cancer Center and Research Institute at University of South Florida; 🇺🇸 Tampa, Florida, United States

Scroll for more (197 remaining)